#Germany #Berlin #HAE #Argo Biopharma #BW-20805

Argo Biopharma's Promising Breakthrough in HAE Treatment

Argo Biopharmaceutical Co., Ltd. recently made headlines with the presentation of positive Phase II trial data for its siRNA therapeutic BW-20805, aimed at treating Hereditary Angioedema (HAE). This important clinical trial data was showcased at the Bradykinin Symposium 2026, held in Berlin, Germany from September 3-4, 2026. The update from the ongoing study is positioned to reshape potential treatment regimens for those suffering from this debilitating condition.

The Significance of BW-20805

BW-20805 is an investigational drug designed to target and silence the messenger RNA of plasma prekallikrein (PKK), a critical pathway involved in HAE. HAE is a rare genetic disorder characterized by unexpected and severe swelling that can affect various body parts and even become life-threatening.

Dr. Dongxu Shu, co-founder and CEO of Argo Biopharma, commented on the significance of the updated results, emphasizing that they reinforce the potential of BW-20805 in providing effective prophylaxis for HAE. The study included various dosing regimens, demonstrating not just efficacy but a well-tolerated safety profile, which is pivotal for bringing necessary therapeutic options to market with less frequent dosing requirements.

A Closer Look at the Phase II Data

The presented Phase II trial involved a global, multicenter, open-label study. Participants were randomized across three different treatment regimens:

• - 600 mg dose every 24 weeks
• - 300 mg dose every 24 weeks
• - 300 mg dose every 12 weeks

As the trial progressed, it became evident that BW-20805 significantly reduced HAE attack rates across all regimens. The mean decrease in time-normalized monthly attack rates was striking, showing reductions of:

• - 83% in the 600 mg every 24 weeks group
• - 96% in the 300 mg every 24 weeks group
• - 93% in the 300 mg every 12 weeks group

These results speak volumes about the therapeutic potential of BW-20805, especially since the attack-free rates indicated notable improvements post-dosing.

Safety and Efficacy at the Forefront

Safety is always a primary concern in clinical trials, and in this study, BW-20805 was generally well tolerated. Out of the 25 subjects enrolled, treatment-emergent adverse events were mild, indicating that the therapeutic approach does not compromise patient safety. Injection-site reactions were the most commonly reported adverse events, but there were no severe incidents that led to discontinuation of the treatment.

The rapid and sustained pharmacodynamic activity of BW-20805 was also highlighted, showcasing a robust and consistent reduction in PKK levels, further corroborating the drug's potential as a game-changer in HAE management.

The Need for Innovative Therapies

The current landscape for HAE treatment often necessitates frequent dosing, which can pose challenges for adherence and overall quality of life for patients. BW-20805, with its promise of less frequent dosing while maintaining efficacy, presents a much-needed option for individuals affected by this rare condition.

According to the latest epidemiological data, HAE affects approximately 1.5 individuals per 100,000. The potential for BW-20805 to alter the course of treatment for this population cannot be overstated.

Conclusion: A Future in HAE Management

As Argo Biopharma continues to push forward with its clinical trials and expand its pipeline of RNAi therapeutics, the results from the Bradykinin Symposium serve as a hopeful beacon for both clinicians and patients alike. The evolving narrative around BW-20805 could indeed forge a new path in the preventive treatment of Hereditary Angioedema, providing lasting effects with improved convenience for patients.

To learn more about Argo Biopharma and its innovative approaches to RNAi therapeutics, visit argobiopharma.com.